Results 131 to 140 of about 113,942 (235)

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis. [PDF]

Onco Targets Ther, 2017
Wang L, Liu Y, Zhou W, Li W.
europepmc   +1 more source

SUDEP and mortality in developmental and epileptic encephalopathies: A meta‐analysis of randomized clinical trials and extension studies

Epilepsia, EarlyView.
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are associated with high premature mortality and increased risk of sudden unexpected death in epilepsy (SUDEP). However, epidemiological data remain limited, particularly for specific syndromes such as Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and infantile epileptic ...
Pierludovico Moro, Maria Sole Borioni, Adolfo Mazzeo, Enrico Cocchi, Carlo Di Bonaventura, Emanuele Cerulli Irelli   +5 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Emergency treatment delay and underdosing are associated with poor outcome in non‐convulsive status epilepticus

Epilepsia, EarlyView.
Abstract Nonconvulsive status epilepticus (NCSE) is difficult to recognize in the emergency department (ED), where onset is often unknown and treatment may be delayed. To what extent treatment timing and dose adequacy are associated with outcome in NCSE remains debated.
Francesco Misirocchi, Alice Ballabeni, Maddalena Frapporti, Alessandro Borgna, Lucia Zinno, Stefano Meletti, Irene Florindo   +6 more
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Artificial intelligence in preclinical epilepsy research: Current state, potential, and challenges

Epilepsia Open, EarlyView.
Abstract Preclinical translational epilepsy research uses animal models to better understand the mechanisms underlying epilepsy and its comorbidities, as well as to analyze and develop potential treatments that may mitigate this neurological disorder and its associated conditions. Artificial intelligence (AI) has emerged as a transformative tool across
Jesús Servando Medel‐Matus, Cesar Santana‐Gomez, Ruby G. Escalante, Dominique Duncan, Pedro F. Viana, Giulia Sofia Cereda, Naoto Kuroda, Aristea S. Galanopoulou   +7 more
wiley   +1 more source

How to report neurotechnology and artificial intelligence studies in epilepsy: Peer‐review‐inspired recommendations

Epilepsia Open, EarlyView.
Abstract Objective The integration of neurotechnology and artificial intelligence (AI) in epilepsy research has led to significant advancements in diagnosis, monitoring, and treatment. However, the impact of these innovations is often diminished by inadequate and inaccurate reporting, limiting their reproducibility and implementation.
Pedro F. Viana, Matthew McWilliam, Andrea Biondi, Jesus Servando Medel‐Matus, Naoto Kuroda, Giulia Sofia Cereda, Aristea S. Galanopoulou   +6 more
wiley   +1 more source

Multi‐Hazard Shaking‐Tsunami Fatality Risk Estimation for Coastal Communities

Earthquake Engineering &Structural Dynamics, EarlyView.
ABSTRACT This study develops a multi‐hazard fatality risk model for a coastal community (Tofino) on Vancouver Island, Canada, subjected to earthquake‐tsunami threats from the Cascadia subduction megathrust events. The model incorporates variable population distributions and uncertain fatality rate models, in addition to other key model components, such
Katsuichiro Goda
wiley   +1 more source

Trendelenburg positioning with or without norepinephrine infusion for haemodynamic support in anaesthetised hypovolemic horses

Equine Veterinary Journal, EarlyView.
Abstract Background Intraoperative haemorrhage during equine anaesthesia is a rare but potentially fatal complication requiring prompt haemodynamic support. Postural manoeuvres such as Trendelenburg (TL) positioning and vasopressor support augment venous return and improve cardiac output (CO), yet their efficacy in anaesthetised hypovolemic horses ...
Vaidehi V. Paranjape, Klaus Hopster, Ismar Lutvikadic, Bernd Driessen   +3 more
wiley   +1 more source